Pixium Vision Appoints Khalid Ishaque as Chief Executive Officer
PARIS, March 25, 2014 /PRNewswire/ –
Pixium Vision (“Pixium”), a developer of innovative Vision Restoration Systems for the
blind, today announces the appointment of Khalid Ishaque as Chief Executive Officer and
Director. Mr Ishaque joins from Boston Scientific, and brings over 22 years of management
experience in the medical technology industry.
Mr Ishaque spent 17 years with Boston Scientific Corporation, where most recently he
was General Manager of its Neuromodulation International business. In this role, he
established and led the international sales and marketing operations for the fast growing
Spinal Cord Stimulation pain management franchise. He also led the global market entry for
Deep Brain Stimulation platform for movement disorders such as Parkinson’s disease and
dystonia. Prior to this, Mr Ishaque was Head of New Business Development for Boston
Scientific in Europe (2001-2007) and was involved in a range of strategic M&A and
technology deals. Mr Ishaque worked for Becton Dickinson for a number of years prior to
joining Boston Scientific in 1997. He received postgraduate degrees in Engineering
(M.Eng.) from Cranfield Institute of Technology in the UK and in International Economics
and Management (MIEM) from SDA Bocconi in Italy.
Bernard Gilly, Pixium’s Executive Chairman, commented: “I am delighted we have been
able to attract someone with Khalid’s experience and track record to become Pixium’s new
CEO. His deep understanding of neuromodulation market and experience of successfully
commercializing new products in this space will be invaluable as we bring our IRIS(R) and
PRIMA(R) Vision Restoration Systems to the market. I am looking forward to working with
Khalid as we strive to deliver on Pixium’s goal of restoring sight and enabling blind
patients to lead more independent lives.”
Khalid Ishaque added: “I am looking forward to working with the world-class
multi-disciplinary team at Pixium that has developed the breakthrough innovations that
comprise Pixium’s IRIS(R) and PRIMA(R) Vision Restoration Systems. Retinal modulation is a
ground-breaking approach to the treatment of blindness caused by photoreceptor
degeneration. I am looking forward to bringing these exciting developments in the
neuromodulation space to the market and witnessing the significant improvements in vision
and autonomy we expect to deliver to blind people.”
About Pixium Vision
Pixium Vision is developing innovative Vision Restoration Systems for blind patients
who have lost their sight with the intention of enabling them to lead more independent
lives. The Company intends to harness the rapid advances being made in visual processing,
micro-electronics, bio-mimetic camera technologies and computing to develop systems that
for blind people could ultimately provide vision approaching that of a normal healthy eye.
Pixium’s technologies are designed to replace dysfunctional or degenerated
photoreceptors in the retina caused by degenerative diseases such as retinitis pigmentosa
and macular degeneration. In these conditions, the remaining retinal cells, the optic
nerve and the vision processing centre in the brain remain intact and able to perceive
vision with the correct stimulation.
The patient wears goggles containing an integrated mini-camera and transmitter. The
captured images are processed by a pocket computer and a signal is transmitted back
through the goggles onto a retinal implant surgically positioned on or within the retina.
The implant stimulates the functional retinal cells, which relay the signals to the brain
to generate ‘vision’. The brain learns to interpret the signals it receives from the
implant during a structured rehabilitation program undertaken by patients.
Pixium’s first system (IRIS(R)) uses an epi-retinal implant (on the retinal surface)
and entered a clinical study in April 2013. Data from the first patients to receive the
implant are expected in 2014 and will form the basis of a CE Mark application.
The Company is also developing a next-generation system (PRIMA(R)), which is based on
a sub-retinal implant (within the retina) and has the potential to further enhance the
Pixium was created in Paris, France in December 2011 following research efforts at the
Vision Institute and Universite Pierre et Marie Curie, as well as collaborative work
involving several leading academic teams from Europe and the USA. Pixium has raised
EUR24.5m from blue-chip European venture capital and investment firms including Sofinnova
Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Bpifrance, Seventure
For more information, go to http://www.pixium-vision.com
IRIS and PRIMA are registered trademarks of Pixium-Vision SA.
SOURCE Pixium Vision